Beijing Centergate Technologies (holding) Investor Relations

Beijing Centergate Technologies (holding) Co., Ltd. engages in the pharmaceutical industry in China and internationally. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Bifonazole API, an opioid receptor antagonist; Naloxone Hydrochloride injection to relieve acute ethanol poisoning; Naltrexone Hydrochloride tablets to block the pharmacological effects of exogenous opioids; Hydrocodone acetaminophen tablets for the treatment of moderate to severe pain; Ambroxol Hydrochloride injection for acute and chronic lung diseases; Tramadol Hydrochloride injection for moderate to severe pain; Febuxostat tablets for long-term treatment of hyperuricemia; and Glipizide Dispersible tablets to improve glycemic control in adults with type 2 diabetes. It also provides Metoprolol succinate API for hypertension and coronary heart disease; Bisoprolol Fumarate tablets for chronic stable heart failure; Tropisetron Mesylate injection for prevention and treatment of nausea and vomiting; Cediodine lozenges used for chronic pharyngitis; Phencynonate Hydrochloride tablets used to prevent motion sickness; Oxycodone Hydrochloride injection, an analgesic; Bifonazole cream used to treat various fungal skin diseases; Huperzine A to improve memory impairment; Wujia Biochemical capsule for vaginal bleeding caused by qi deficiency and blood stasis; Lactobacillus tablets used for abnormal intestinal fermentation; Tramadol Hydrochloride tablets for the treatment of pain in adults; Aminophene Tramadol tablets for treatment of moderate to severe acute pain; Clindamycin phosphate vaginal gel used to treat bacterial vaginosis; and Benidipine Hydrochloride tablets for essential hypertension and angina pectoris. Beijing Centergate Technologies (holding) Co., Ltd. was founded in 1999 and is based in Beijing, China.

Read Less